Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon, Ltd.

http://www.biocon.com/

Latest From Biocon, Ltd.

Semglee's Boost On Express Scripts Formulary Reflects Interchangeability – And Rebates

First interchangeable insulin biosimilar gains preferred status on one of the largest national formularies in the US.

Biosimilars Commercial

Biocon Insulin Plant Gets FDA Form 483s As Aspart Awaits Action

Six Form 483 observations of GMP deficiencies have been received from the US FDA by Biocon after the agency inspected the Malaysian manufacturing facility for its insulin aspart biosimilar. However, the Indian firm – which is partnered with Viatris on the product, for which an interchangeability designation is also being sought – insisted that US commercialization plans would not be affected.

Manufacturing Biosimilars

UK Travel Rule Sparks Row As India Seeks To Resume COVID-19 Vaccine Diplomacy

As India gets set to resume COVID-19 vaccine diplomacy from October, a new rule which will require Indians visiting UK who are fully vaccinated with AstraZeneca partner Serum Institute’s vaccine to undergo quarantine has sparked a row. Meanwhile, Indian companies await a nod from the WHO for wider acceptance of their COVID-19 vaccines.

Policy Coronavirus COVID-19

Biocon Chief Extols Moderna’s Success To Spur ‘Risk-Averse’ VCs in India

Biocon chairperson Kiran Mazumdar-Shaw says that venture capital firms have, with their risk-averse approach, "failed" the biotech sector in India. The executive draws attention to how "bold" venture funds that backed mRNA technology a decade ago were reaping gains today.

Commercial Coronavirus COVID-19
See All

Company Information

  • Industry
  • Biotechnology
  • Distributors
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Biocon Sdn Bhd.
    • Biocon Limited
    • Biocon Biologics India Ltd
    • Bicara Therapeutics
UsernamePublicRestriction

Register